ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

OCLG Oncologix Tech Inc (CE)

0.0001
0.00 (0.00%)
27 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Oncologix Tech Inc (CE) USOTC:OCLG OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0001 0.00 00:00:00

Termination of Registration of a Class of Security Under Section 12(g) (15-12g)

23/08/2017 9:32pm

Edgar (US Regulatory)


 

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION

12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE

REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 0-15482

 

ONCOLOGIX TECH, INC.

(Name of Small Business Issuer as Specified in Its Charter)

 

PO Box 8832

Grand Rapids, MI 49518-8832

(616) 977-9933

(Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)

 

COMMON STOCK, PAR VALUE, $0.001 PER SHARE

(Title of each class of securities covered by this Form)

 

NONE

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

  Rule 12g-4(a)(1) [X]
  Rule 12g-4(a)(2) [  ]
  Rule 12h-3(b)(1)(i) [X]
  Rule 12h-3(b)(1)(ii) [  ]
  Rule 15d-6 [  ]
  Rule 15d-22(b) [  ]

 

Approximate number of holders of record as of the certification or notice date: 105

 

Pursuant to the requirements of the Securities Exchange Act of 1934 (Name of registrant as specified in charter) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

August 23, 2017

 

  ONCOLOGIX TECH, INC.
   
  By: /s/ Michael A. Kramarz
    Michael A. Kramarz
    Chief Financial Officer

 

 

 

 
 

 

1 Year Oncologix Tech (CE) Chart

1 Year Oncologix Tech (CE) Chart

1 Month Oncologix Tech (CE) Chart

1 Month Oncologix Tech (CE) Chart

Your Recent History

Delayed Upgrade Clock